RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
C4 Therapeutics Stock

C4 Therapeutics ROE 2024

C4 Therapeutics ROE

-0.54

Ticker

CCCC

ISIN

US12529R1077

In 2024, C4 Therapeutics's return on equity (ROE) was -0.54, a 21.46% increase from the -0.44 ROE in the previous year.

C4 Therapeutics Aktienanalyse

What does C4 Therapeutics do?

The company C4 Therapeutics Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts. The company specializes in the development of drugs that work based on targeted protein degradation. This approach aims to specifically break down proteins in the body that are associated with various diseases. C4 Therapeutics develops special molecules that bind to these proteins and help break them down. The company's business model is based on collaboration with other companies in the pharmaceutical industry, where they develop drug candidates and license them to other companies for further development and marketing. C4 Therapeutics has a specialized strategy to become a leader in the field of targeted protein degradation. They are currently active in various areas, including the development of cancer drugs with a focus on proteins responsible for tumor growth, as well as neurology drugs for diseases like Alzheimer's and Parkinson's. Their important development is the PROTAC platform technology, which allows targeted protein degradation by binding two different molecules to the protein, triggering a cascade of reactions that lead to protein breakdown. Overall, C4 Therapeutics is an innovative and dynamic company specializing in drug development based on targeted protein degradation, with promising potential to treat a range of diseases. Despite being relatively young, the company has already achieved numerous successes and is expected to play an important role in the pharmaceutical industry in the future. C4 Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding C4 Therapeutics's Return on Equity (ROE)

C4 Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing C4 Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

C4 Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in C4 Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about C4 Therapeutics stock

What is the ROE (Return on Equity) of C4 Therapeutics this year?

The ROE of C4 Therapeutics this year is -0.54 undefined.

How has the Return on Equity (ROE) of C4 Therapeutics developed compared to the previous year?

The ROE of C4 Therapeutics has increased by 21.46% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of C4 Therapeutics?

A high ROE indicates that C4 Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of C4 Therapeutics?

A low ROE can indicate that C4 Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of C4 Therapeutics affect the company?

A change in ROE (Return on Equity) of C4 Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of C4 Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of C4 Therapeutics?

Some factors that can influence C4 Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does C4 Therapeutics pay?

Over the past 12 months, C4 Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, C4 Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of C4 Therapeutics?

The current dividend yield of C4 Therapeutics is .

When does C4 Therapeutics pay dividends?

C4 Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of C4 Therapeutics?

C4 Therapeutics paid dividends every year for the past 0 years.

What is the dividend of C4 Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is C4 Therapeutics located?

C4 Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von C4 Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of C4 Therapeutics from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did C4 Therapeutics pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of C4 Therapeutics in the year 2023?

In the year 2023, C4 Therapeutics distributed 0 USD as dividends.

In which currency does C4 Therapeutics pay out the dividend?

The dividends of C4 Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von C4 Therapeutics

Our stock analysis for C4 Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of C4 Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.